African-Americans were much less likely to undergo potentially life-saving surgery in Georgia if they lived in heavily segregated areas. » Read More
Billionaire investor William Ackman faced close questioning on Wednesday when he detailed his hedge fund's biggest-ever quarterly loss.
A failed $160 billion merger between Pfizer and Allergan left experts contemplating whether more deals could be hit by new tax rules.
Valeant Pharmaceuticals said a committee completed a review of its accounting practices and did not find anything that would require restatements.
Republican presidential candidates say they want to dismantle the Affordable Care Act. But investors might not be buying the rhetoric.
The "Fast Money" traders give their final trades of the day.
Zika shouldn't have caught us by surprise, writes Dr. Claire Pomeroy. Here's what needs to be done to prevent the next killer virus.
The U.S. has a long way to go as it tries to a solution to the spread of Zika, CDC Director Thomas Frieden says.
For the first time, the number of obese people around the world now is greater than the number of undernourished, according to a study in The Lancet.
Hollywood star Whoopi Goldberg is launching a line of female-focused cannabis products aimed at relieving menstrual pain.
GlaxoSmithKline is to adopt a graduated approach to patenting its medicines depending on the wealth of different countries.
It's hoped the FDA will approve an artificial pancreas in 2017. The device is expected to transform treatment of type 1 diabetes.
Two hedge fund "quants" have come up with an algorithm that diagnoses heart disease from MRI images.
Two phony cancer charities that swindled donors out of more than $75 million will be dissolved, NBC News reports.
The "Fast Money" traders give their final trades and get ready for the final day of the quarter.
The founder of 2015's best-performing hedge fund gives his best biotech bet heading into April and also says Hillary Clinton is wrong about drug pricing.
"Maude" creator Norman Lear can't believe a woman’s right to choose is still under fire. It has a huge impact on their lives and careers.
ValueAct, an activist investment firm, paid the price for being a longtime investor in Valeant Pharmaceuticals, says the New York Times.
A study found that Theranos produces more irregular results than conventional laboratories, The New York Times reports.
A program that paid patients cash to get lower-cost treatments earned insurers a 7-to-1 return on their investment.
U.S. legislators have asked William Ackman's hedge fund for information on Valeant, according to a person familiar with the matter.
Get the best of CNBC in your inbox